Orexigen Therapeutics, Inc.

On May 31, 2019, Orexigen Therapeutics, Inc., went out of business as per its Chapter 11 liquidation filing under bankruptcy. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.